<DOC>
	<DOCNO>NCT00995410</DOCNO>
	<brief_summary>This study use open-label design conduct approximately 40 site United States . Approximately 400 subject enrol study ensure approximately 300 subject 6 month exposure PA32540 least 100 subject 12 month exposure PA32540 .</brief_summary>
	<brief_title>Study Evaluate Long-Term Safety PA32540 Subjects Who Are Risk Developing Aspirin-Associated Gastric Ulcers</brief_title>
	<detailed_description>PA32540 propose secondary prevention cardio- cerebrovascular event patient risk develop aspirin-associated gastric ulcer . This study design provide long-term safety data PA32540 order gain regulatory approval make PA32540 available clinical use subject population .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Inclusion criterion : 1 . A . Male nonpregnant , nonbreastfeeding female daily aspirin 325 mg least three month expect use daily aspirin 325 mg least six month ( Daily define `` least 5 day per week '' ) : AND , 55 year age old ; 18 54 year age history document gastric duodenal ulcer within past five year . 2 . A. Aspirin use secondary prevention cardiovascular cerebrovascular event define follow : Have diagnose history MI ( myocardial infarction confirm suspect ) Ischemic stroke TIA ( transient ischemic attack ) Or establish , clinically significant coronary atherosclerotic vascular disease ( mean high risk surgical intervention MI , TIA , stroke , leave untreated ) , include : Angina ( stable unstable ) Peripheral arterial disease Atherosclerotic aortic disease Carotid artery disease Or CABG ( coronary artery bypass graft ) PCI ( percutaneous coronary intervention without stent ) Carotid endarterectomy 3 . A . If female , subject eligible 1. nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) ; , 2. childbearing potential , negative pregnancy test screening , least one follow applies agree subject : Female sterilization sterilization male partner Hormonal contraception oral route , implant , injectable , vaginal ring Any intrauterine device ( IUD ) publish data show low expected failure rate le 1 % per year Double barrier method ( 2 physical barrier 1 physical barrier plus spermicide ) Any method publish data show low expected failure rate le 1 % per year 4 . Able understand comply study procedure require able willing provide write informed consent prior study procedure perform Exclusion criterion : 1 . Any current gastric , esophageal duodenal ulcer 2 . Positive test result H. pylorus screen 3A . Have revascularization procedure ( i.e. , Coronary Artery Bypass Graft , Percutaneous Transluminal Coronary Angioplasty , carotid endarterectomy ) less six month prior screen 4 . Unstable hypertension judge Investigator 5 . Uncontrolled diabetes mellitus judge Investigator 6 . Unstable cardio cerebrovascular disease would endanger subject participate trial 7 . Clinically significant valvular disease 8 . Congestive heart failure cardiovascular symptom accord New York Heart Association ( NYHA ) Functional Classification IIIIV ( Appendix 3 ) 9 . History hypersensitivity omeprazole another proton pump inhibitor 10 . History allergic reaction intolerance aspirin and/or history aspirininduced symptom asthma , rhinitis , and/or nasal polyp 11 . History serious UGI event , bleeding , perforation , obstruction 12 . Gastrointestinal disorder surgery lead impaired drug absorption 13 . Presence chronic uncontrolled acute medical illness , e.g . gastrointestinal disorder ( esophageal stricture , severe esophagitis , longsegment Barrett 's esophagus , sign symptom gastric outlet obstruction ) , thyroid disorder and/or infection would endanger subject participate study 14 . Schizophrenia , uncontrolled bipolar disorder , severe depression 15 . History alcoholism drug addiction within year prior enrollment study 16 . Severe hepatic dysfunction ( i.e . cirrhosis portal hypertension ) 17 . Blood coagulation disorder , include use systemic anticoagulant warfarin vitamin K antagonists 18 . Any condition , opinion Investigator , may either put subject risk influence result study 19 . Use excluded concomitant medication ( see Section 9.2 ) 20 . Screening laboratory ALT AST value &gt; two time upper limit normal 21A . History renal insufficiency 22 . Other note specifically , screen laboratory value clinically significant Investigator 's opinion would endanger subject subject participate study 23 . Use investigational treatment 4 week screen 24 . History malignancy , treat untreated , within past five year , exception successfully treat basal cell squamous cell carcinoma skin 25 . Previous participation another PA32540 clinical research study 26 . Subjects , employee research facility , immediately related Investigator , way supervision Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Subjects Who Risk Developing Aspirin-ASA</keyword>
	<keyword>Subject must pre-existing condition aspirin already indicate</keyword>
	<keyword>Gastric Ulcers</keyword>
</DOC>